Last Updated: November 9, 2026

CLINICAL TRIALS PROFILE FOR MITOTANE

« Back to Dashboard

All Clinical Trials for mitotane

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001339 ↗	A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection	Completed	National Cancer Institute (NCI)	Phase 2	1993-08-01	Patients who have no response to preoperative chemotherapy and no residual disease following surgery on Regimen A are treated on Regimen B postoperatively. The following acronyms are used: DDD Mitotane, NSC-38721 DOX Doxorubicin, NSC-123127 VCR Vincristine, NSC-67574 VP-16 Etoposide, NSC-141540 Regimen A: 4-Drug Combination Chemotherapy followed by Surgery followed by 4-Drug Combination Chemotherapy. DDD/DOX/VCR/VP-16; followed by surgical debulking; followed by DDD/DOX/VCR/VP-16. Regimen B: Single-Agent Chemotherapy. DDD.
NCT00002921 ↗	S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery	Terminated	National Cancer Institute (NCI)	Phase 2	1997-03-01	RATIONALE: Some tumors need growth factors produced by the body to keep growing. Suramin may interfere with the growth factor and stop the tumor from growing. PURPOSE: Phase II trial to study the effectiveness of suramin in treating patients with stage III or stage IV adrenocortical cancer.
NCT00002921 ↗	S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery	Terminated	Southwest Oncology Group	Phase 2	1997-03-01	RATIONALE: Some tumors need growth factors produced by the body to keep growing. Suramin may interfere with the growth factor and stop the tumor from growing. PURPOSE: Phase II trial to study the effectiveness of suramin in treating patients with stage III or stage IV adrenocortical cancer.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for mitotane

Condition Name

Chart
Table

Condition Name for mitotane
Intervention	Trials
Adrenocortical Carcinoma	12
Adrenal Cortical Carcinoma	3
Stage III Adrenocortical Carcinoma	2
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for mitotane
Intervention	Trials
Adrenocortical Carcinoma	22
Carcinoma	17
Adrenal Cortex Neoplasms	4
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for mitotane

Trials by Country

Map
Table

Trials by Country for mitotane
Location	Trials
United States	84
Italy	8
Canada	7
Brazil	3
Germany	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for mitotane
Location	Trials
Maryland	7
Michigan	6
Texas	5
Ohio	3
New York	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for mitotane

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for mitotane
Clinical Trial Phase	Trials
PHASE2	3
Phase 4	1
Phase 3	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for mitotane
Clinical Trial Phase	Trials
Recruiting	9
Completed	8
Not yet recruiting	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for mitotane

Sponsor Name

Chart
Table

Sponsor Name for mitotane
Sponsor	Trials
National Cancer Institute (NCI)	9
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia	5
M.D. Anderson Cancer Center	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for mitotane
Sponsor	Trials
Other	38
NIH	9
Industry	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.